Loading…
Themis Medicare (THEMISMED)₹101.58+0.99%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Themis Medicare reported sales of ₹87.18 Cr, down 11.1% from Jun 2025, and net profit of ₹24.97 Cr. For the year to Mar 2026, sales were ₹342 Cr and net profit ₹0.99 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 105 | 83.13 | 98.22 | 123 | 117 | 94.11 | 72.07 | 98.11 | 78.17 | 90.14 | 77.09 | 87.18 |
| Expenses | 92.14 | 74.07 | 89.09 | 94.17 | 100 | 88.11 | 79.15 | 108 | 81.13 | 80.13 | 73.08 | 139 |
| Operating Profit | 12.01 | 8.01 | 9.01 | 29.05 | 17.01 | 6.01 | −8.01 | −10.01 | −3.01 | 10.01 | 4.01 | −52.05 |
| OPM % | 12.0% | 9.9% | 10.0% | 23.9% | 15.0% | 6.0% | −11.1% | −10.1% | −4.0% | 10.9% | 4.9% | −60.1% |
| Other Income | 6.99 | 5.99 | 4.99 | 6.99 | 5.99 | 0.99 | 1.99 | 0.99 | 4.99 | 5.99 | 10.98 | 96.78 |
| Interest | 2.01 | 3.01 | 2.01 | 2.01 | 2.01 | 3.01 | 2.01 | 2.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| Depreciation | 3.01 | 3.01 | 3.01 | 2.01 | 2.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| Profit before tax | 13.96 | 7.98 | 8.98 | 30.89 | 17.95 | 1.99 | −10.96 | −13.97 | −2.99 | 9.97 | 8.97 | 38.89 |
| Tax % | 18.9% | 9.9% | 24.0% | 20.9% | 19.9% | 68.9% | −13.1% | 1.0% | 5.0% | 3.0% | 2.0% | 35.9% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −0.99 | 0.00 | 78.78 |
| Net Profit | 10.99 | 6.99 | 6.99 | 24.96 | 13.98 | 0.99 | −9.99 | −13.98 | −3.99 | 9.99 | 8.99 | 24.97 |
| EPS (Rs) | 1.22 | 0.79 | 0.71 | 2.67 | 1.54 | 0.05 | −1.04 | −1.53 | −0.38 | 1.09 | 0.96 | 2.66 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 232 | 217 | 210 | 184 | 202 | 231 | 395 | 354 | 383 | 406 | 342 | 333 |
| Expenses | 194 | 184 | 184 | 181 | 166 | 181 | 300 | 287 | 330 | 357 | 342 | 373 |
| Operating Profit | 38.05 | 33.06 | 25.02 | 2.01 | 36.04 | 49.05 | 96.13 | 67.10 | 52.08 | 49.06 | 0.00 | −41.04 |
| OPM % | 16.0% | 14.9% | 12.0% | 1.2% | 18.0% | 21.0% | 24.0% | 18.9% | 13.0% | 11.9% | 0.1% | −12.3% |
| Other Income | 2.99 | 3.99 | 5.99 | 4.99 | 11.99 | 12.97 | 17.97 | 24.98 | 23.98 | 10.99 | 22.96 | 119 |
| Interest | 12.02 | 12.03 | 12.03 | 12.02 | 13.03 | 13.03 | 9.02 | 10.02 | 9.03 | 10.02 | 11.03 | 12.04 |
| Depreciation | 12.06 | 7.03 | 7.03 | 8.03 | 8.03 | 9.04 | 9.04 | 10.03 | 12.04 | 10.04 | 10.04 | 12.04 |
| Profit before tax | 16.95 | 17.94 | 10.97 | −12.96 | 26.89 | 40.84 | 94.71 | 72.76 | 52.86 | 39.87 | 1.99 | 54.84 |
| Tax % | 10.9% | 8.9% | 1.0% | −15.1% | 8.0% | 14.0% | 23.0% | 21.9% | 19.0% | 25.0% | 40.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 | 0.00 | 0.99 | 2.99 | 0.99 | 0.00 | −0.99 | 77.79 |
| Net Profit | 15.99 | 15.98 | 10.99 | −10.99 | 24.98 | 35.99 | 72.87 | 56.95 | 43.92 | 29.96 | 0.99 | 39.96 |
| EPS (Rs) | 1.90 | 1.76 | 1.22 | −1.16 | 2.69 | 3.87 | 7.89 | 6.16 | 4.71 | 3.23 | 0.11 | 4.33 |
| Dividend payout % | 9.0% | 0.0% | 0.0% | 0.0% | 6.0% | 11.0% | 6.0% | 8.0% | 11.0% | 15.0% | 404.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.98 | 8.97 | 8.96 | 8.97 | 8.97 | 8.97 | 8.97 | 8.97 | 8.96 | 8.96 | 8.97 | 8.97 |
| Reserves | 51.18 | 66.27 | 143 | 160 | 149 | 174 | 210 | 278 | 331 | 369 | 394 | 390 |
| Borrowings | 140 | 128 | 82.00 | 80.06 | 82.08 | 100 | 87.07 | 80.00 | 92.11 | 96.03 | 83.05 | 100 |
| Other Liabilities | 76.74 | 72.75 | 53.74 | 55.73 | 73.68 | 66.68 | 64.69 | 60.71 | 81.60 | 92.55 | 102 | 98.53 |
| Total Liabilities | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 589 | 599 |
| Fixed Assets | 122 | 117 | 124 | 126 | 123 | 116 | 133 | 144 | 162 | 168 | 172 | 167 |
| CWIP | 3.99 | 5.98 | 8.97 | 1.99 | 1.99 | 7.98 | 1.99 | 2.99 | 2.99 | 2.99 | 2.99 | 1.99 |
| Investments | 4.99 | 5.99 | 22.99 | 23.96 | 26.98 | 34.97 | 44.94 | 55.94 | 69.95 | 88.93 | 94.94 | 109 |
| Other Assets | 146 | 146 | 133 | 153 | 162 | 191 | 192 | 225 | 280 | 308 | 319 | 321 |
| Inventories | 62.09 | 58.15 | 48.10 | 50.07 | 54.10 | 55.11 | 58.14 | 61.12 | 69.13 | 71.10 | 84.20 | 81.19 |
| Trade receivables | 46.13 | 48.15 | 48.11 | 69.11 | 73.21 | 102 | 78.16 | 101 | 145 | 178 | 177 | 178 |
| Cash & equivalents | 9.01 | 14.01 | 9.01 | 7.01 | 3.01 | 5.01 | 25.01 | 26.01 | 19.02 | 19.03 | 13.01 | 9.01 |
| Total Assets | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 589 | 599 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 19.01 | 25.99 | −1.99 | 7.99 | 10.99 | 0.00 | 56.96 | 33.97 | 15.98 | 21.99 | 34.97 | −2.99 |
| Cash from investing activity | −5.98 | −6.98 | −3.99 | 0.00 | −3.99 | −4.99 | −15.95 | −15.95 | −23.95 | −15.97 | −11.98 | −2.99 |
| Cash from financing activity | −18.01 | −12.99 | 5.01 | −8.99 | −10.01 | 7.01 | −25.99 | −18.01 | 0.00 | −8.99 | −25.98 | 3.99 |
| Net cash flow | −4.99 | 4.99 | 0.00 | −0.99 | −2.99 | 1.99 | 15.99 | 1.01 | −7.99 | −2.99 | −2.99 | −1.99 |
| Capex | 6.31 | 7.99 | 5.45 | 9.64 | 5.65 | 5.83 | 18.09 | 20.69 | 28.83 | 18.48 | 15.48 | 4.88 |
| Free cash flow | 13.01 | 18.02 | −7.01 | 5.01 | 5.01 | −4.99 | 39.04 | 15.02 | −12.99 | 3.99 | 21.02 | −8.01 |
| CFO / OP % | 101.0% | 73.0% | −5.0% | 29.0% | 490.0% | 2.0% | 115.0% | 55.0% | 48.0% | 60.0% | 93.0% | 781.9% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 82 | 75 | 81 | 120 | 145 | 186 | 123 | 93 | 149 | 170 | 159 | 190 |
| Inventory days | 246 | 243 | 250 | 253 | 287 | 315 | 272 | 150 | 213 | 188 | 233 | 229 |
| Days payable | 237 | 145 | 163 | 156 | 187 | 171 | 143 | 79 | 123 | 126 | 142 | 143 |
| Cash conversion cycle | 91 | 172 | 168 | 216 | 244 | 330 | 251 | 164 | 239 | 232 | 250 | 275 |
| Working capital days | −19 | −16 | −15 | 20 | 0 | 38 | 52 | 73 | 111 | 115 | 122 | 139 |
| ROCE % | 9.0% | 15.0% | 13.0% | 10.0% | −1.0% | 15.0% | 18.0% | 30.0% | 20.0% | 14.0% | 10.0% | 3.0% |
For the Jun 2026 quarter, Themis Medicare reported sales of ₹87.18 Cr, down 11.1% year on year and net profit of ₹24.97 Cr. The operating margin was −60.1%.
Themis Medicare's sales for the year to Mar 2026 were ₹342 Cr; over the last twelve months they were ₹333 Cr.
Net profit for the year to Mar 2026 was ₹0.99 Cr, and ₹39.96 Cr over the last twelve months. Earnings per share over the same trailing period were ₹4.33.
Themis Medicare reported borrowings of ₹100 Cr at Mar 2026, against cash and equivalents of ₹9.01 Cr.
Cash from operations was −₹2.99 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹8.01 Cr.